BRAF and non-small cell lung carcinoma: For example, following its approval in chronic myelogenous leukemia, imatinib was successfully repurposed for KIT-mutant gastrointestinal stromal tumors (18), and dabrafenib plus trametinib was repositioned for BRAF V600-mutated anaplastic thyroid cancer (19) after the approval of this combination in non-small cell lung cancer (NSCLC) and melanoma.